The utility of assessing gene expression in skin to evaluate treatment response: What becomes of all those skin biopsies? Monique Hinchcliff, MD MS Associate Clinical Director and Director of Translational Research Northwestern Scleroderma Program Patient Education Day October 15, 2016
22
Embed
Gene Expression and Treatment in Scleroderma : What Becomes of all those Skin Biopsies
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
The utility of assessing gene expression in skin to evaluate treatment response:
What becomes of all those skin biopsies?
Monique Hinchcliff, MD MSAssociate Clinical Director and
Director of Translational ResearchNorthwestern Scleroderma Program
Patient Education DayOctober 15, 2016
Overview
• How we currently measure skin disease• Why/how we perform skin biopsies• What have we learned
– Novel gene expression signature• Distinguish between SSc patients and healthy subjects• Correlates with skin score • Provides a metric to assess real-time clinical
improvement
19yo woman with Systemic Sclerosis (SSc)/Scleroderma
Patient attempting to make fist
Patient attempting to straighten fingers
modified Rodnan skin score
Problems: confounding, time to change, inter- and intra-relater variability